Commercial-stage, biopharmaceutical company HUTCHMED (China) Limited (Nasdaq:HCM)(AIM:HCM)(HKEX:13) and Innovent Biologics, Inc. (HKEX:1801), a biopharmaceutical company, on Tuesday jointly announce New Drug Application, (NDA) acceptance in China for fruquintinib combination with sintilimab in advanced endometrial cancer, granted Priority Review after Breakthrough Therapy designation in July 2023.
This marks the first regulatory filing for fruquintinib in combination with a leading immune checkpoint inhibitor. The NDA targets patients with advanced endometrial cancer who are not eligible for curative surgery or radiation.
The submission is based on data from FRUSICA-1, a Phase II study evaluating the combination's efficacy and safety. Primary endpoints include objective response rate, with secondary endpoints covering various clinical and pharmacokinetic assessments. Breakthrough Therapy designation was granted due to the combination's potential in addressing an unmet medical need with significant clinical advantages. Fruquintinib, a selective oral VEGFR inhibitor, shows promise in inhibiting tumor angiogenesis with enhanced selectivity and sustained target inhibition, potentially expanding its utility in combination therapies.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation